new_0222_0695|CNTB|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0695|CNTB|1|Connect Biopharma Holdings Ltd Total Current Assets (Quarterly) (USD)|Connect Biopharma Holdings Ltd Cash and Short Term Investments (Quarterly) (USD)|Connect Biopharma Holdings Ltd Inventories (Quarterly) (USD)|Connect Biopharma Holdings Ltd Net PP&E (Quarterly) (USD)|Connect Biopharma Holdings Ltd Goodwill and Intangibles (Quarterly) (USD)|Connect Biopharma Holdings Ltd Total Liabilities (Quarterly) (USD)|Connect Biopharma Holdings Ltd Total Current Liabilities (Quarterly) (USD)|Connect Biopharma Holdings Ltd Total Long Term Liabilities (Quarterly) (USD)|Connect Biopharma Holdings Ltd Total Deposits (Quarterly) (USD)|Connect Biopharma Holdings Ltd Book Value (Quarterly) (USD)|Connect Biopharma Holdings Ltd Retained Earnings (Quarterly) (USD)|Connect Biopharma Holdings Ltd Treasury Stock (Quarterly) (USD)|Connect Biopharma Holdings Ltd EV to Revenues|Connect Biopharma Holdings Ltd EV to Earnings|Connect Biopharma Holdings Ltd EV to Free Cash Flow|Connect Biopharma Holdings Ltd EV to Assets (Quarterly)|Connect Biopharma Holdings Ltd PS Ratio|Connect Biopharma Holdings Ltd PE Ratio|Connect Biopharma Holdings Ltd Price to Book Value|Connect Biopharma Holdings Ltd PEG Ratio|Connect Biopharma Holdings Ltd Debt to Equity Ratio|Connect Biopharma Holdings Ltd Dividend Yield|Connect Biopharma Holdings Ltd Shareholder Yield (TTM)|Connect Biopharma Holdings Ltd Percent of Shares Outstanding Short|Connect Biopharma Holdings Ltd Total Receivables (Quarterly) (USD)|Connect Biopharma Holdings Ltd Total Payables (Quarterly) (USD)|Connect Biopharma Holdings Ltd Total Capital Stock (Quarterly) (USD)|Connect Biopharma Holdings Ltd Return on Invested Capital|Connect Biopharma Holdings Ltd Quality Ratio Score|Connect Biopharma Holdings Ltd Momentum Score|Connect Biopharma Holdings Ltd Beta (1Y)|Connect Biopharma Holdings Ltd Sustainable Growth Rate (TTM)|Connect Biopharma Holdings Ltd Institutional Investor Ownership Percentage|Connect Biopharma Holdings Ltd Average Diluted Shares Outstanding (Quarterly)|Connect Biopharma Holdings Ltd Total Employees (Annual)|Connect Biopharma Holdings Ltd EPS Diluted (Quarterly) (USD)|Connect Biopharma Holdings Ltd SG&A Expense (Quarterly) (USD)|Connect Biopharma Holdings Ltd Shares Outstanding|Connect Biopharma Holdings Ltd Repurchase of Capital Stock (Quarterly) (USD)|Connect Biopharma Holdings Ltd Ordinary Shares Number (Quarterly)|Connect Biopharma Holdings Ltd Payout Ratio|Connect Biopharma Holdings Ltd Quick Ratio (Quarterly)|Connect Biopharma Holdings Ltd Normalized Diluted EPS (Quarterly) (USD)|Connect Biopharma Holdings Ltd Stock Buybacks (Quarterly) (USD)|Connect Biopharma Holdings Ltd Effective Tax Rate (TTM)|Connect Biopharma Holdings Ltd Return on Equity|Connect Biopharma Holdings Ltd Net Income (TTM) (USD)|Connect Biopharma Holdings Ltd Revenue (TTM) (USD)|Connect Biopharma Holdings Ltd Dividend Per Share (Quarterly) (USD)|Connect Biopharma Holdings Ltd Revenue (Quarterly) (USD)|Connect Biopharma Holdings Ltd Gross Profit (Quarterly) (USD)|Connect Biopharma Holdings Ltd Pre-Tax Income (Quarterly) (USD)|Connect Biopharma Holdings Ltd Net Income (Quarterly) (USD)|Connect Biopharma Holdings Ltd Net Interest Income (Quarterly) (USD)|Connect Biopharma Holdings Ltd Price (USD)|Connect Biopharma Holdings Ltd Total Return Price (USD)|Connect Biopharma Holdings Ltd Enterprise Value (USD)|Connect Biopharma Holdings Ltd 30-Day Average Daily Volume|Connect Biopharma Holdings Ltd 1 Year Price Returns (Daily)|Connect Biopharma Holdings Ltd Short Interest|Connect Biopharma Holdings Ltd PE Ratio (Forward)|Connect Biopharma Holdings Ltd PE Ratio (Forward 1y)|Connect Biopharma Holdings Ltd PS Ratio (Forward)|Connect Biopharma Holdings Ltd PS Ratio (Forward 1y)|Connect Biopharma Holdings Ltd Quarterly EPS Estimates (USD)|Connect Biopharma Holdings Ltd Quarterly Revenue Estimates (USD)|Connect Biopharma Holdings Ltd Quarterly EPS Surprise|Connect Biopharma Holdings Ltd Quarterly Revenue Surprise|Connect Biopharma Holdings Ltd Quarterly Actual EPS (USD)|Connect Biopharma Holdings Ltd Quarterly Actual Revenue (USD)|Connect Biopharma Holdings Ltd Revenue Estimates for Current Fiscal Year (USD)|Connect Biopharma Holdings Ltd Revenue Estimates for Next Fiscal Year (USD)|Connect Biopharma Holdings Ltd Price Target (USD)|Connect Biopharma Holdings Ltd Consensus Recommendation|Connect Biopharma Holdings Ltd Price Target Num Estimates|Connect Biopharma Holdings Ltd EPS Estimates for Current Fiscal Year (USD)|Connect Biopharma Holdings Ltd EPS Estimates for Next Fiscal Year (USD)|Connect Biopharma Holdings Ltd Research and Development Expense (Quarterly) (USD)|Connect Biopharma Holdings Ltd Reconciled Depreciation (Quarterly) (USD)|Connect Biopharma Holdings Ltd Non-Operating Interest Expense (Quarterly) (USD)|Connect Biopharma Holdings Ltd Land and Improvements (Quarterly) (USD)|Connect Biopharma Holdings Ltd Buildings and Improvements (Quarterly) (USD)|Connect Biopharma Holdings Ltd Other Properties (Quarterly) (USD)|Connect Biopharma Holdings Ltd Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0695|CNTB|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0695|CNTB|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0695|CNTB|5|181|181||181|181|181|181|181||181|181|181|||1.44206008584||||1.43827160494|||1.44206008584||15.3|181|181|181||||||30.6|||||22||181|||||181||181||||||||1.44206008584|1.44206008584|1.44206008584|1.44117647059||15.3|||||91|91.3333333333|||||98|147|51.6666666667|23.8461538462|51.6666666667|73.5|89.3333333333||||||181|181||
new_0222_0695|CNTB|6|1|1||1|1|1|1|1||1|1|1|||233||||162|||233||20|1|1|1||||||10|||||5||1|||||1||1||||||||233|233|233|204||20|||||1|6|||||3|2|6|13|6|4|3||||||1|1||
new_0222_0695|CNTB|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0695|CNTB|202012|161.7558|156.6045||2.6737|0.0523|322.9323|5.8159|317.1165||-156.8801|-163.9816|0.0005|||||||||||||0.265|4.4852|0.0037||||||||62|||||53.9417|||||||-116.7848||||||||||||||||||||||||||||||||||||1.0104|0.0895||
new_0222_0695|CNTB|202103|||||||||||||||-33.6049|||||||||1.3438|||||||||50.5254|||||57.5042|||||||||||||||||18.5|18.5|907.2232|280236.3333||772727|||||-0.21||||||||29.6667|1.3333|3|-1.13|-2.15||||||||16.27|14.88
new_0222_0695|CNTB|202106|324.504|313.228||6.182|3.4793|14.0923|14.0178|0.0746||322.1331|-311.4919|0.0005|||-12.324||||3.4851|||||1.3481|0.408|10.4865|0.0102||||||57.416|||||57.4834||57.4834|||||||-252.0471||||||||19.53|19.53|809.4228|53303.7||774912|||||-0.25||||||||29|1.3333|4|-1.007|-1.7185||||||3.4303|0.5493|22.01|23.47
new_0222_0695|CNTB|202109|||||||||||||||-16.4375||||4.3237|||||1.4877|||||||||60.8678||||||||||||||||||||||24.23|24.23|1079.5947|52399.2||855165|||||||||||||29.25|1.25|4|-3.77|-1.8485||||||||15.84|4.35
new_0222_0695|CNTB|202112|||||||||||||||0.2617||||0.919|||||0.4739|||||||||60.1264||||||||||||||||||||||5.15|5.15|-17.1885|619008.8||272408|||||||||||||23.25|1.25|4|-1.7335|-2.31||||||||4.6|4.51
new_0222_0695|CNTB|202203||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
new_0222_0695|CNTB|202206||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
new_0222_0695|CNTB|202209||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||